HK Stock Market Move | CARSGEN-B(02171) increased by more than 12%. The first generalized CAR-T recipient evaluated at sCR at four weeks based on the THANK-u Plus platform.

CARSGEN-B(02171) rose more than 12%, up to 12.85% at the time of publication, trading at 10.54 Hong Kong dollars, with a turnover of 27.70 million Hong Kong dollars. On the news front, Koji Pharmaceutical announced today that the first patient enrolled in the clinical trial of a universal BCMA CAR-T developed based on the THANK-u Plus platform achieved a strict complete response (sCR) and minimal residual disease (MRD) negativity at the 28-day visit for efficacy evaluation. The THANK-u Plus platform is a universal CAR-T technology platform developed by Koji Pharmaceutical to address the accessibility issue of CAR-T. The CAR-T product is planned to be used for the treatment of relapsed/refractory multiple myeloma (R/R MM) or relapsed/refractory plasma cell leukemia (R/R PCL). The company estimates that more data information will be shared in the second half of this year. The patient had relapsed/refractory multiple myeloma of IgA- type (R-ISS stage II), and had previously received third-line combination drug therapy and autologous hematopoietic stem cell transplantation. The patient enrolled in the clinical trial after disease progression following the last treatment. The patient experienced Grade 1 CRS after receiving the lowest dose group of CAR-T cell infusion in the clinical protocol, and recovered after receiving antipyretics and tocilizumab treatment. No ICANS or other CAR-T-related adverse reactions were observed, and overall safety was good.